Amicus announces U.K. approval, launch of Pompe disease drug | Seeking Alpha
Pompe News | Pompe Support Network
MHRA marketing authorization granted to Amicus' Pompe disease treatment
Amicus drug for Pompe disease falls short in key clinical trial
SEC Filing | Amicus Therapeutics
FDA Clears Amicus Therapeutics' Pompe Disease Treatment
g45154moi001.gif
Amicus' Pompe approval portends a showdown with Sanofi
FDA OKs Amicus Pompe combo, setting up market battle with Sanofi
Amicus Updates Data from AT-GAA Phase 3 PROPEL Trial
SEC Filing | Amicus Therapeutics
Amicus Therapeutics secures $430M deal with Blackstone for Pompe disease combination treatment. | Pharmtales | Pharma News & Analysis posted on the topic | LinkedIn
Pompe Disease » Powell Center for Rare Disease Research and Therapy » College of Medicine » University of Florida
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease | Amicus Therapeutics
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease | Amicus Therapeutics
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics' Pombiliti + Opfolda for Treatment of Pompe Disease | Muscular Dystrophy Association
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Amicus Therapeutics Raising Awareness about Pompe Disease in April
Amicus gets positive CHMP opinion for Opfolda to treat Pompe disease
Pompe disease: Amicus and Paragon agree to develop gene technologies
Pompe Disease Therapeutic Market Report 2022:2028 – Industry Growth Forecasts by Manufacturers, Countries, Type and Application | Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, - Digital Journal
Amicus Therapeutics wins EC approval of Opfolda for Pompe disease | Seeking Alpha
Curing Pompe and Helping His Kids the Mission of Amicus CEO
